GenVec Inc. to Present at 25th Annual ROTH Conference
Published: Mar 12, 2013
GAITHERSBURG, Md., March 12, 2013 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) announced today that Cindy Collins, GenVec's President and CEO, will present a Company overview highlighting recent developments starting at 4:00 p.m. PDT/7:00 p.m. EDT on Tuesday, March 19th at the upcoming 25th Annual ROTH OC Growth Stock Conference in Laguna Niguel, California.
A webcast of Ms. Collins' presentation will be available both live and on replay. The presentation will be available via webcast at http://wsw.com/webcast/roth27/gnvc/. A replay will also be available for 90 days following the live presentation. The live webcast and subsequent archived replay of GenVec's presentation will also be accessible via the Investors and Media section of the Company's web site at http://ir.genvec.com under "Events & Presentations."
GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.
Retail Investor and Media Contact:
Institutional Investor Contact:
S.A. Noonan Communications
Douglas J. Swirsky
Susan A. Noonan
SOURCE GenVec, Inc.